Outcome of Board Meeting
AMRUTANJAN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.9 pts more than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Amrutanjan Health Care reported audited FY2026 results with revenue from operations of Rs 50,255.27 lakhs, up 11.2% from Rs 45,181.63 lakhs in FY2025. Profit after tax grew 13.9% to Rs 5,791.78 lakhs from Rs 5,083.47 lakhs, with EPS at Rs 20.03 (vs Rs 17.58). The Board recommended a final dividend of Rs 2.90 per share. Two exceptional items totaling Rs 885.67 lakhs were recorded: Rs 760.50 lakhs for retrospective lease rent revision (one-time impact for Tamil Nadu land lease) and Rs 125.17 lakhs due to new labour codes. The auditors (BSR & Co. LLP) issued an unmodified opinion. The Board also appointed Mr. Ramaswami Krishnan as Additional Independent Director, re-appointed Mr. Muralidharan Swayambunathan for a second term, approved a revised ESOP 2 scheme, and appointed PKF Sridhar & Santhanam as internal auditors.
Strong bottom-line growth with PAT up ~14% and positive cash generation of Rs 3,596.77 lakhs from operations. Exceptional items are non-recurring and do not affect core operations. Dividend and director appointments are positive governance signals for shareholders.